Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Evidence and Research Comparison# Mazdutide Research# Mazdutide was approved in China in June 2025 for weight management, making it the first GLP-1/glucagon dual agonist to receive regulatory approval anywhere: Phase 3 obesity (China) : Up to 20.1% body weight reduction at the 9 mg dose over 60 weeks
Published studies have investigated retatrutide as a ligand with activity reported across GLP 1, GIP, and glucagon receptors, with research interest spanning energy balance and glucose regulation pathways
GLP-3), lean mass loss was reported at ~38.2% at higher doses
Namun, saat ini banyak uji klinis juga telah membandingkan efektivitas liraglutide dan semaglutide, yang sama-sama merupakan agonis reseptor GLP-1.[1-3] Pada bulan Juni 2021, FDA menyetujui injeksi semaglutide 2,4 mg secara subkutan dengan dosis 1 kali seminggu sebagai tambahan terapi diet rendah kalori dan aktivitas fisik
The availability of both subcutaneous and oral formulations further enhances treatment adherence and accessibility
Zepbound is a prescription medication approved for long-term weight management in adults who meet certain criteria
US$ 24.90
US$ 21.58
US$ 22.76
US$ 29.89
US$ 23.31
US$ 25.76
US$ 29.20
US$ 25.32
US$ 24.45
